Plan sponsors race to manage GLP-1 surge before specialty drug bills explode
GLP-1 drugs that began as diabetes treatments now sit at the centre of a much bigger cost story for employer drug plans in 2026.
Plan sponsors already see the impact of GLP‑1 receptor agonists for type 2 diabetes and weight management.
According to a recent report by Alberta Blue Cross, the pipeline now shows these drugs moving into conditions such as metabolic dysfunction–associated steatohepatitis (MASH) and obstructive sleep apnea (OSA), while a second wave of products targets obesity plus multiple cardio‑renal and metabolic co‑morbidities.
Semaglutide 2.4mg (Wegovy) now carries Health Canada approval not only for weight loss and cardiovascular risk reduction, but also for MASH.
MASH affects an estimated 5–6 percent of Canadians, and studies show roughly one in three overweight or obese patients have it.
Untreated, it can progress to cirrhosis, liver cancer or the need for a liver transplant.
Wegovy uses the same dosing for MASH as for its existing indications, at about $5,000 a year.
Tirzepatide (Zepbound), currently indicated for weight management, is under Health Canada review for OSA.
OSA affects about 20 percent of Canadians, often goes undiagnosed and increases cardiometabolic risk. Maintenance dosing at 10–15mg weekly would likely cost about $6,800–$9,800 a year.
Behind these label expansions sits a broader GLP‑1 pipeline.
Late‑stage products such as Maridebart (MariTide), CagriSema, high‑dose semaglutide 7.2mg, orforglipron, retatrutide and survodutide target obesity, cardiovascular disease with obesity, chronic kidney disease, back pain, osteoarthritis, MASH and other complications.
Most are not yet before Health Canada, but their trial status signals continued pressure on drug budgets as indications broaden beyond diabetes and obesity.
Generic entry will help, but only at the margins. Generic liraglutide and semaglutide are expected in 2026, though generic semaglutide is already delayed until mid‑2026.
Novo Nordisk has also secured Health Canada approval for Plosbrio and Poviztra—formulations identical to Ozempic and Wegovy—with pricing expected below the originals to compete with generics.
Given rising utilization, more indications and new molecules, overall GLP‑1 spend is unlikely to fall.
High‑cost biologics are following a similar trajectory, moving into chronic, high‑prevalence conditions with long treatment durations.
In respiratory disease, depemokimab is under Health Canada review and positioned as the first ultra‑long‑acting biologic for obstructive airway disease, with dosing every 6 months rather than every 2–4 weeks.
It is submitted as an add‑on maintenance treatment for type 2 inflammatory asthma in adults and adolescents, and for adults with inadequately controlled chronic rhinosinusitis with nasal polyps.
Existing biologics are also adding indications that will expand eligibility:
-
Dupilumab (Dupixent), already used in atopic dermatitis, chronic rhinosinusitis with nasal polyps, severe asthma, eosinophilic esophagitis and prurigo nodularis, is now approved for eosinophilic COPD and chronic spontaneous urticaria, at an estimated annual cost of about $23,500 (300mg every 2 weeks).
-
Mepolizumab (Nucala) is under review for eosinophilic COPD, with current dosing at 100mg every 4 weeks costing about $26,000 a year.
-
Tezepelumab (Tezspire) is under review for chronic rhinosinusitis with nasal polyps, at about $24,000 a year for 210mg every 4 weeks.
In neurology, two products stand out for their potential impact on high‑cost, long‑term care pathways.
Tolebrutinib, an oral once‑daily Bruton’s tyrosine kinase inhibitor, is under review for non‑relapsing secondary progressive multiple sclerosis (nrSPMS) to slow disability progression even without relapses.
If approved, it would be the first therapy specifically indicated for nrSPMS, addressing a major treatment gap.
Pricing remains unknown.
Leqembi (lecanemab), approved in October 2025 at about $32,000 per year, is the first disease‑modifying therapy for Alzheimer’s disease.
It targets amyloid beta pathology and must be started in mild cognitive impairment or mild dementia due to Alzheimer’s.
Its use requires specialized clinicians, MRI imaging, genetic testing and infusion infrastructure, and treatment should stop once patients progress to moderate disease.
Beyond drug cost, this has implications for disability, long‑term care and coordination with public programs.
Rare disease drugs continue to emerge with extremely high price tags.
Examples under Health Canada review include Imaavy for generalized Myasthenia Gravis at about US$324,480 a year for a 75kg person, Tryngolza for familial chylomicronemia syndrome at about US$595,000 a year, Yorvipath for hypoparathyroidism at about US$285,000 a year, Lyvdelzi for primary biliary cholangitis at about $86,000 a year and Voxzogo for achondroplasia at about $320,000 a year.
These products demand tight criteria, mandatory use of public funding where available and strong case management.
Against this backdrop, generics and biosimilars remain key tools.
The Pan‑Canadian Tiered Pricing Framework allows oral solid generics to fall to as low as 25 percent of brand when three or more competitors are on the market, and to 35 percent for other dosage forms.
Notable first‑entry generics under review include products in diabetes (Invokana, Jardiance, Synjardy, Trajenta, Jentadueto), cardiovascular disease, central nervous system conditions and fertility.
A golimumab biosimilar to Simponi is also under review; Simponi costs about $18,000–$20,000 a year, so biosimilar competition should reduce spending in inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis.
